Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review
Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Medwave Estudios Limitada
2012-09-01
|
Series: | Medwave |
Subjects: | |
Online Access: | http://dx.doi.org/10.5867/medwave.2012.08.5472 |
id |
doaj-dda48daf705744aa8e58a2d6bc203ab2 |
---|---|
record_format |
Article |
spelling |
doaj-dda48daf705744aa8e58a2d6bc203ab22020-11-24T23:46:49ZengMedwave Estudios LimitadaMedwave0717-63842012-09-011208e5472Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic reviewJosé CallejaJosé UribarriIntroduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of methylphenidate (MPH) in ADHD in the 6-19 year-old population. Methods: A systematic review of intervention studies was conducted with time limit February, 2012, in English and Spanish. The following databases were consulted: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators and were assessed for methodological quality. Results: Of the 377 studies found initially, 14 were included, including two systematic reviews, 7 primary articles on therapeutic interventions and 5 clinical guidelines. Most of the studies have shortcoming with regards to search strategies, critical analysis, small samples and low Jadad scale. Conclusions: MPH is superior to placebo for moderate to severe cases of ADHD in the of 6-19 year-old population. http://dx.doi.org/10.5867/medwave.2012.08.5472attention deficit disorder with hyperactivitymethylphenidatesystematic review |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
José Calleja José Uribarri |
spellingShingle |
José Calleja José Uribarri Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review Medwave attention deficit disorder with hyperactivity methylphenidate systematic review |
author_facet |
José Calleja José Uribarri |
author_sort |
José Calleja |
title |
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review |
title_short |
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review |
title_full |
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review |
title_fullStr |
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review |
title_full_unstemmed |
Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review |
title_sort |
effectiveness and safety of methylphenidate for adhd in population between 6 and 19 years: a systematic review |
publisher |
Medwave Estudios Limitada |
series |
Medwave |
issn |
0717-6384 |
publishDate |
2012-09-01 |
description |
Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacologic and non-pharmacologic interventions. Methylphenidate is the most widely used drug and is available to most patients. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of methylphenidate (MPH) in ADHD in the 6-19 year-old population. Methods: A systematic review of intervention studies was conducted with time limit February, 2012, in English and Spanish. The following databases were consulted: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators and were assessed for methodological quality. Results: Of the 377 studies found initially, 14 were included, including two systematic reviews, 7 primary articles on therapeutic interventions and 5 clinical guidelines. Most of the studies have shortcoming with regards to search strategies, critical analysis, small samples and low Jadad scale. Conclusions: MPH is superior to placebo for moderate to severe cases of ADHD in the of 6-19 year-old population. |
topic |
attention deficit disorder with hyperactivity methylphenidate systematic review |
url |
http://dx.doi.org/10.5867/medwave.2012.08.5472 |
work_keys_str_mv |
AT josecalleja effectivenessandsafetyofmethylphenidateforadhdinpopulationbetween6and19yearsasystematicreview AT joseuribarri effectivenessandsafetyofmethylphenidateforadhdinpopulationbetween6and19yearsasystematicreview |
_version_ |
1725492104565620736 |